The Role of rituximab for newly diagnosed, refractory or relapsed aggressive B-cell lymphoma in adult patients

Christina Fitzmaurice, Richard Zinke, Bradley Heraly, Brad Kahl

Research output: Contribution to journalArticle

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: The objective of this systematic review was to assess the efficacy (OS, PFS, EFS, RR), safety (rate of cytopenias, transfusions, fever, antibiotic use, infusion reactions, secondary malignancies) and QOL of standard chemotherapy regimens (CHOP and other chemotherapy regimens) with and without rituximab for aggressive B-cell lymphoma in adult patients.

Original languageEnglish
Article numberCD009347
JournalCochrane Database of Systematic Reviews
Volume2016
Issue number12
DOIs
StatePublished - Dec 8 2016
Externally publishedYes

Fingerprint Dive into the research topics of 'The Role of rituximab for newly diagnosed, refractory or relapsed aggressive B-cell lymphoma in adult patients'. Together they form a unique fingerprint.

  • Cite this